Suppr超能文献

儿童功能性恶心和功能性消化不良的药物治疗:系统评价。

Pharmacological treatments for functional nausea and functional dyspepsia in children: a systematic review.

机构信息

a Emma Children's Hospital, Amsterdam UMC , University of Amsterdam, Pediatric Gastroenterology , Amsterdam , The Netherlands.

b Research Support, Medical Library , Amsterdam UMC, University of Amsterdam , Amsterdam , The Netherlands.

出版信息

Expert Rev Clin Pharmacol. 2018 Dec;11(12):1195-1208. doi: 10.1080/17512433.2018.1540298. Epub 2018 Dec 6.

Abstract

INTRODUCTION

Chronic idiopathic nausea (CIN) and functional dyspepsia (FD) cause considerable strain on many children's lives and their families. Areas covered: This study aims to systematically assess the evidence on efficacy and safety of pharmacological treatments for CIN or FD in children. CENTRAL, EMBASE, and Medline were searched for Randomized Controlled Trials (RCTs) investigating pharmacological treatments of CIN and FD in children (4-18 years). Cochrane risk of bias tool was used to assess methodological quality of the included articles. Expert commentary: Three RCTs (256 children with FD, 2-16 years) were included. No studies were found for CIN. All studies showed considerable risk of bias, therefore results should be interpreted with caution. Compared with baseline, successful relief of dyspeptic symptoms was found for omeprazole (53.8%), famotidine (44.4%), ranitidine (43.2%) and cimetidine (21.6%) (p = 0.024). Compared with placebo, famotidine showed benefit in global symptom improvement (OR 11.0; 95% CI 1.6-75.5; p = 0.02). Compared with baseline, mosapride versus pantoprazole reduced global symptoms (p = 0.011; p = 0.009). One study reported no occurrence of adverse events. This systematic review found no evidence to support the use of pharmacological drugs to treat CIN or FD in children. More high-quality clinical trials are needed.

ABBREVIATIONS

AP-FGID: Abdominal Pain Related Functional Gastrointestinal Disorders; BART: Biofeedback-Assisted Relaxation Training; CIN: Chronic Idiopathic Nausea; COS: Core Outcomes Sets; EPS: Epigastric Pain Syndrome; ESPGHAN: European Society for Pediatric Gastroenterology Hepatology and Nutrition; FAP: Functional Abdominal Pain; FD: Functional Dyspepsia; GERD: Gastroesophageal Reflux Disease; GES: Gastric Electrical Stimulation; HRAs: H2 Receptor Antagonists; IBS: irritable bowel syndrome; NASPGHAN: North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition; PDS: Postprandial Distress Syndrome; PPIs: Proton Pump Inhibitor; PROMs: Patient Reported Outcome Measures; RCTs: Randomized Controlled Trials; SSRIs: selective serotonin reuptake inhibitors; TCAs: tricyclic antidepressants.

摘要

简介

慢性特发性恶心(CIN)和功能性消化不良(FD)给许多儿童及其家庭带来了相当大的压力。

涵盖领域

本研究旨在系统评估药物治疗儿童 CIN 或 FD 的疗效和安全性的证据。CENTRAL、EMBASE 和 Medline 检索了针对儿童(4-18 岁)CIN 和 FD 的药物治疗的随机对照试验(RCT)。使用 Cochrane 偏倚风险工具评估纳入文章的方法学质量。

专家评论

纳入了三项 RCT(256 名 FD 患儿,2-16 岁)。未发现 CIN 的研究。所有研究均显示出相当大的偏倚风险,因此结果应谨慎解释。与基线相比,奥美拉唑(53.8%)、法莫替丁(44.4%)、雷尼替丁(43.2%)和西咪替丁(21.6%)成功缓解消化不良症状(p=0.024)。与安慰剂相比,法莫替丁在整体症状改善方面显示出益处(OR 11.0;95%CI 1.6-75.5;p=0.02)。与基线相比,莫沙必利与泮托拉唑相比可减少整体症状(p=0.011;p=0.009)。一项研究报告无不良事件发生。本系统评价未发现支持使用药物治疗儿童 CIN 或 FD 的证据。需要更多高质量的临床试验。

缩写

AP-FGID:腹痛相关功能性胃肠病;BART:生物反馈辅助放松训练;CIN:慢性特发性恶心;COS:核心结局集;EPS:上腹痛综合征;ESPGHAN:欧洲小儿胃肠病、肝病和营养学会;FAP:功能性腹痛;FD:功能性消化不良;GERD:胃食管反流病;GES:胃电刺激;HRAs:H2 受体拮抗剂;IBS:肠易激综合征;NASPGHAN:北美小儿胃肠病、肝病和营养学会;PDS:餐后不适综合征;PPIs:质子泵抑制剂;PROMs:患者报告的结局测量;RCTs:随机对照试验;SSRIs:选择性 5-羟色胺再摄取抑制剂;TCAs:三环类抗抑郁药。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验